|
|
|
Insider
Information: |
Pfreundschuh Peter P. |
Relationship: |
|
City: |
Morris Plains |
State: |
NJ |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
6 |
|
Direct
Shares |
270,707 |
|
Indirect Shares
|
0 |
|
|
Direct
Value |
$4,367,043 |
|
|
Indirect Value
|
$0 |
|
|
Total
Shares |
270,707 |
|
|
Total
Value |
$4,367,043 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
2
|
Stock
price went up :
|
0
|
1
|
Stock
price went down : |
0
|
1
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
-85.7%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Immunomedics Inc |
IMMU |
Chief Financial Officer |
2015-08-20 |
29,706 |
2014-08-14 |
0 |
Premium* |
|
Sucampo Pharmaceuticals, Inc. |
SCMP |
CFO |
2018-02-13 |
0 |
2017-09-30 |
0 |
Premium* |
|
Urogen Pharma Ltd. |
URGN |
Chief Financial Officer |
2020-10-15 |
10,405 |
2019-08-20 |
0 |
Premium* |
|
Korro Bio |
KRRO |
Chief Financial Officer |
2022-02-22 |
8,927 |
2022-02-14 |
0 |
Premium* |
|
Voyager Therapeutics, Inc. |
VYGR |
Chief Financial Officer |
2024-02-21 |
175,669 |
2022-10-01 |
0 |
Premium* |
|
Y-Mabs Therapeutics Inc |
YMAB |
|
2024-07-12 |
46,000 |
2024-07-12 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
35 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 2 of 2
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
KRRO |
Korro Bio |
Chief Financial Officer |
|
2022-02-16 |
4 |
S |
$4.43 |
$5,443 |
D/D |
(1,229) |
13,169 |
0 |
- |
|
KRRO |
Korro Bio |
Chief Financial Officer |
|
2022-02-17 |
4 |
S |
$4.20 |
$5,443 |
D/D |
(1,296) |
11,873 |
0 |
- |
|
KRRO |
Korro Bio |
Chief Financial Officer |
|
2022-02-18 |
4 |
S |
$3.88 |
$5,443 |
D/D |
(1,404) |
10,469 |
0 |
- |
|
KRRO |
Korro Bio |
Chief Financial Officer |
|
2022-02-22 |
4 |
S |
$3.53 |
$5,442 |
D/D |
(1,542) |
8,927 |
0 |
- |
|
VYGR |
Voyager Therapeutics, Inc... |
Chief Financial Officer |
|
2022-10-01 |
4 |
A |
$0.00 |
$0 |
D/D |
125,000 |
125,000 |
0 |
- |
|
VYGR |
Voyager Therapeutics, Inc... |
Chief Financial Officer |
|
2023-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
38,000 |
163,000 |
0 |
- |
|
VYGR |
Voyager Therapeutics, Inc... |
Chief Financial Officer |
|
2023-10-03 |
4 |
S |
$6.99 |
$94,833 |
D/D |
(13,567) |
149,433 |
0 |
% |
|
VYGR |
Voyager Therapeutics, Inc... |
Chief Financial Officer |
|
2024-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
179,433 |
0 |
- |
|
VYGR |
Voyager Therapeutics, Inc... |
Chief Financial Officer |
|
2024-02-21 |
4 |
S |
$7.46 |
$28,079 |
D/D |
(3,764) |
175,669 |
0 |
% |
|
YMAB |
Y-Mabs Therapeutics Inc |
CFO and Treasurer |
|
2024-07-12 |
4 |
A |
$0.00 |
$0 |
D/D |
46,000 |
46,000 |
0 |
- |
|
35 Records found
|
|
Page 2 of 2 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|